Laura Rosanò

Laura Rosanò

Auto-generated profile, based on publicly available information

Laura Rosanò

Translational Research Functional Departmental Area, Regina Elena National Cancer Institute, Rome, Italy

Research Focus & Metrics

Academic Career Length

30Years (1997-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2013 in Nature Reviews Cancer
Verified
Journal Article
Closed access
LRLaura Rosanò
Laura Rosanò
FSFrancesca Spinella
Francesca Spinella
ABAnna Bagnato
Anna Bagnato

1 November 2000 in The American Journal of Pathology
Verified
Journal Article
Closed access
DSDebora Salani
Debora Salani
GTGiulia Taraboletti
Giulia Taraboletti
LRLaura Rosanò
Laura Rosanò
VCValeriana Di Castro
Valeriana Di Castro
PBPatrizia Borsotti
Patrizia Borsotti
ABAnna Bagnato
Anna Bagnato

14 April 2011 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
LRLaura Rosanò
Laura Rosanò
RCRoberta Cianfrocca
Roberta Cianfrocca
FSFrancesca Spinella
Francesca Spinella
VCValeriana Di Castro
Valeriana Di Castro
MNMaria Rita Nicotra
Maria Rita Nicotra
ABAnna Bagnato
Anna Bagnato
Purpose: Emerging evidence suggests molecular and phenotypic association between chemoresistance and epithelial–mesenchymal transition (EMT) in cancer. Endothelin-1 (ET-1)/endothelin A receptor (ETAR) axis is implicated in the pathobiology of epithelial ovarian cancer (EOC) by driving tumor-promoting effects, including EMT. Here, we analyzed how ETAR regulates chemoresistance and EMT in EOC.

1 August 2002 in Journal of Biological Chemistry
Verified
Journal Article
Open access
FSFrancesca Spinella
Francesca Spinella
LRLaura Rosanò
Laura Rosanò
VCValeriana Di Castro
Valeriana Di Castro
PNPier Giorgio Natali
Pier Giorgio Natali
ABAnna Bagnato
Anna Bagnato
Angiogenesis is an essential prerequisite for tumor growth, invasion, and metastasis. In ovarian carcinoma cells, endothelin-1 (ET-1) stimulates the secretion of vascular endothelial growth factor (VEGF), a major mediator of tumor angiogenesis. In OVCA 433 and HEY ovarian carcinoma cell lines, ET-1 treatment increases VEGF mRNA expression and induces VEGF protein levels in a time- and dose-dependent fashion, and do so to a greater extent under hypoxic conditions. ET-1 also increases hypoxia-inducible factor-1alpha (HIF-1alpha) accumulation and activates the HIF-1 transcription complex under both normoxic and hypoxic conditions, suggesting a role for HIF-1 in the induction of VEGF expression. These effects are inhibited by the selective ET(A) receptor (ET(A)R) antagonist, BQ123. The ET-1-induced increase in HIF-1alpha protein levels is due to the enhanced HIF-1alpha stabilization. These results implicate HIF-1alpha in the induction of VEGF expression in ET-1-stimulated ovarian carcinoma cells, and provide a mechanism whereby ET-1 acting selectively through ET(A)R can interact with the HIF-1alpha-dependent machinery of angiogenesis. Our results suggest that new therapeutic strategies using specific ET(A)R antagonists could provide an additional approach to the treatment of ovarian carcinoma by inhibiting neovascularization as well as tumor cell growth.

1 January 2008 in The International Journal of Biochemistry & Cell Biology
Verified
Journal Article
Closed access
ABAnna Bagnato
Anna Bagnato
LRLaura Rosanò
Laura Rosanò

24 February 2009 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LRLaura Rosanò
Laura Rosanò
RCRoberta Cianfrocca
Roberta Cianfrocca
SMStefano Masi
Stefano Masi
FSFrancesca Spinella
Francesca Spinella
VCValeriana Di Castro
Valeriana Di Castro
ABAnna Bagnato
Anna Bagnato
The activation of endothelin-A receptor (ETAR) by endothelin-1 (ET-1) has a critical role in ovarian tumorigenesis and progression. To define the molecular mechanism in ET-1-induced tumor invasion and metastasis, we focused on β-arrestins as scaffold and signaling proteins of G protein-coupled receptors. Here, we demonstrate that, in ovarian cancer cells, β-arrestin is recruited to ETAR to form two trimeric complexes: one through the interaction with Src leading to epithelial growth factor receptor (EGFR) transactivation and β-catenin Tyr phosphorylation, and the second through the physical association with axin, contributing to release and inactivation of glycogen synthase kinase (GSK)-3β and β-catenin stabilization. The engagement of β-arrestin in these two signaling complexes concurs to activate β-catenin signaling pathways. We then demonstrate that silencing of both β-arrestin-1 and β-arrestin-2 inhibits ETAR-driven signaling, causing suppression of Src, mitogen-activated protein kinase (MAPK), AKT activation, as well as EGFR transactivation and a complete inhibition of ET-1-induced β-catenin/TCF transcriptional activity and cell invasion. ETAR blockade with the specific ETAR antagonist ZD4054 abrogates the engagement of β-arrestin in the interplay between ETAR and the β-catenin pathway in the invasive program. Finally, ETAR is expressed in 85% of human ovarian cancers and is preferentially co-expressed with β-arrestin-1 in the advanced tumors. In a xenograft model of ovarian metastasis, HEY cancer cells expressing β-arrestin-1 mutant metastasize at a reduced rate, highlighting the importance of this molecule in promoting metastases. ZD4054 treatment significantly inhibits metastases, suggesting that specific ETAR antagonists, by disabling multiple signaling activated by ETAR/β-arrestin, may represent new therapeutic opportunities for ovarian cancer.